President & Chief Executive Officer
Mr. Baharaff is the co‐founder of Galmed, and has served as CEO since 2012, and President as of 2015. Previously, he held a number of senior executive positions, including SVP at Isramex Projects Ltd., and Managing Director of T+M Trusteeship & Management. He also serves as a Director of the Tel‐Aviv Museum of Arts and Executive Director at The Rubin Museum.
Mr. Baharaff holds a Bachelor of Science degree from the University of London (LSE) and LLB and MA degrees from Cambridge University. Since 1993, Mr. Baharaff has been a member of the Israel Bar Association.
Liat Hayardeny, Ph.D.
Chief Scientific Officer
Dr. Hayardeny joined Galmed in 2016 bringing more than 16 years of experience in drug development as part of Teva Pharmaceuticals’ global R&D Division. Prior to joining Galmed, Dr. Hayardeny served as Teva’s Senior Director and Head of Research Scientific Affairs. In that capacity, Dr. Hayardeny established the scientific positioning of Teva’s innovative compounds. Additionally, Dr. Hayardeny was responsible for the company’s relationship with institutions of higher education; managing Teva’s global research collaborations and publications. Dr. Hayardeny holds a Ph.D. from Sackler School of Medicine and an MBA from Recanati Business School at Tel Aviv University.
Chief Financial Officer
Mr. Stenzler joined Galmed in 2014 and has served as Galmed’s Chief Financial Officer since February 2017. Prior to joining Galmed, Mr. Stenzler was an accountant at Ernst & Young LLP, where he was involved in financing, taxes, auditing, advising and accounting of public and private companies, both domestic and international. Mr. Stenzler is a certified CPA and holds an MBA in Finance from Recanati Business School at Tel Aviv University, and a BA in Economics and Accounting from Ben‐Gurion University.
Tali Gorfine, M.D.
Chief Medical Officer
Dr. Gorfine joined Galmed 2016. Prior to joining Galmed, she served as a Senior Clinical Program Leader at Teva R&D. In that capacity, she led product strategy and clinical development in the field of multiple sclerosis and was responsible for large Phase II and III studies. Dr. Gorfine holds an MD., and a PhD in the field of functional magnetic resonance imaging (fMRI) from the Tel‐Aviv University.
Chief Operating Officer
Mr. Nehemya joined Galmed in 2013 as Galmed’s Director of Operations and has served as the Company’s Vice President, Operations since March 2017. Mr. Nehemya was a key member of management during the Company’s IPO. Mr. Nehemya holds an MBA from Arison School of Business at IDC Herzliya and an LL.B. from the College of Management. Mr. Nehemya has been a member of the Israeli Bar Association since 2012.
Joseph Kaspi Ph.D.
Senior CMC Director
Dr. Kaspi joined Galmed in December 2016 bringing with him rich experience of more than 35 years in process development of pharmaceutical active ingredients (API). Dr. Kaspi held positions of VP for R&D and Chief Scientific Officer in Perrigo API (formerly Chemagis). Earlier he served as process development leader in the chemical section of Teva R&D. A Ph.D. degree in organic chemistry from the Hebrew University in Jerusalem is held by him.